[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Eric S. Fain, a director of Orchestra BioMed Holdings, Inc. (OBIO), reported an acquisition of 5,760 shares of the company's common stock at a weighted-average price of $2.61 per share. Following this transaction the reporting person beneficially owns 71,709 shares indirectly through the Fain Living Trust. The filing identifies the purchase as multiple transactions aggregated to a weighted-average price and notes the reporting person is filing individually as a director. No derivative transactions, dispositions, or other changes in ownership are reported in this Form 4.
Eric S. Fain, amministratore di Orchestra BioMed Holdings, Inc. (OBIO), ha comunicato l'acquisto di 5.760 azioni ordinarie della societ脿 a un prezzo medio ponderato di 2,61 USD per azione. Dopo questa operazione, la persona che ha presentato la segnalazione detiene beneficiariamente 71.709 azioni indirettamente tramite il Fain Living Trust. La dichiarazione indica che l'acquisto 猫 il risultato di pi霉 operazioni aggregate in un prezzo medio ponderato e precisa che la segnalazione 猫 stata effettuata a titolo personale in qualit脿 di amministratore. In questo Modulo 4 non sono riportate transazioni in strumenti derivati, cessioni n茅 altri cambiamenti nella propriet脿.
Eric S. Fain, director de Orchestra BioMed Holdings, Inc. (OBIO), inform贸 la adquisici贸n de 5.760 acciones ordinarias de la compa帽铆a a un precio promedio ponderado de 2,61 USD por acci贸n. Tras esta operaci贸n, la persona informante posee de forma beneficiaria 71.709 acciones indirectamente a trav茅s del Fain Living Trust. El formulario se帽ala que la compra corresponde a varias transacciones agregadas a un precio promedio ponderado y aclara que la persona presenta la declaraci贸n a t铆tulo individual como director. En este Formulario 4 no se registran operaciones con derivados, enajenaciones ni otros cambios de propiedad.
鞓れ紑鞀ろ姼霛� 氚旍澊鞓る⿺霌� 頇�霐╈姢(Orchestra BioMed Holdings, Inc., OBIO)鞚� 鞚挫偓鞚� Eric S. Fain鞚� 氤错喌欤� 5,760欤茧ゼ 欤茧嫻 臧�欷戫弶攴犼皜瓴� 2.61雼煬鞐� 旆摑頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 鞚� 瓯半灅 頉� 鞁犼碃鞚胳潃 Fain Living Trust毳� 韱淀暣 臧勳爲鞝侅溂搿� 齑� 71,709欤茧ゼ 鞁れ 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊電� 頃措嫻 毵れ瀰鞚� 鞐煬 瓯半灅毳� 臧�欷戫弶攴犼皜瓴╈溂搿� 歆戧硠頃� 瓴冹瀯鞚� 氚濏瀳瓿� 鞛堨溂氅�, 鞁犼碃鞚胳潃 鞚挫偓搿滌劀 臧滌澑 氇呾潣搿� 鞁犼碃頃橁碃 鞛堨潓鞚� 氇呾嫓頃╇媹雼�. 鞚� Form 4鞐愳劀電� 韺岇儩靸來拡 瓯半灅, 觳橂秳 霕愲姅 旮绊儉 靻岇湢甓� 氤�瓴届潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
Eric S. Fain, administrateur d'Orchestra BioMed Holdings, Inc. (OBIO), a d茅clar茅 l'acquisition de 5 760 actions ordinaires de la soci茅t茅 au prix moyen pond茅r茅 de 2,61 USD par action. 脌 la suite de cette op茅ration, la personne d茅clarante poss猫de 脿 titre b茅n茅ficiaire 71 709 actions indirectement via le Fain Living Trust. Le d茅p么t pr茅cise que cet achat correspond 脿 plusieurs transactions agr茅g茅es en un prix moyen pond茅r茅 et indique que la personne d茅pose la d茅claration 脿 titre individuel en tant qu'administrateur. Aucune transaction d茅riv茅e, cession ou autre changement de propri茅t茅 n'est signal茅 dans ce Formulaire 4.
Eric S. Fain, Director von Orchestra BioMed Holdings, Inc. (OBIO), meldete den Erwerb von 5.760 Stammaktien des Unternehmens zu einem gewichteten Durchschnittspreis von 2,61 USD je Aktie. Nach dieser Transaktion besitzt die meldende Person wirtschaftlich 71.709 Aktien indirekt 眉ber den Fain Living Trust. Die Meldung weist darauf hin, dass der Kauf aus mehreren Transaktionen zu einem gewichteten Durchschnittspreis zusammengefasst wurde und dass die meldende Person individuell als Director meldet. In diesem Formular 4 sind keine Derivatgesch盲fte, Ver盲u脽erungen oder sonstigen 脛nderungen der Eigentumsverh盲ltnisse angegeben.
- Director purchase recorded: Reporting person acquired 5,760 shares of common stock, indicating a board member increased exposure to the company's equity.
- Clear price disclosure: Weighted-average price reported as $2.61 with a disclosed purchase range of $2.60 to $2.61, providing transparency about execution prices.
- Beneficial ownership disclosed: Total beneficial ownership of 71,709 shares is stated and identified as held indirectly via the Fain Living Trust.
- None.
Insights
TL;DR: Director added 5,760 shares at a $2.61 weighted-average price, modestly increasing indirect ownership to 71,709 shares.
The acquisition is a straightforward open-market purchase reported on Form 4. The filing shows only non-derivative shares were acquired and the shares are held indirectly via a trust. Because the report lists a weighted-average price and states purchases occurred at $2.60 to $2.61, it appears the transactions were executed over multiple trades at nearly identical prices. The disclosure does not include any sales, option exercises, or additional derivative instruments.
TL;DR: A company director increased indirect shareholdings via a trust by 5,760 common shares, now totaling 71,709 beneficially owned shares.
This Form 4 is limited to a non-derivative purchase and confirms the reporting relationship as a director and that ownership is indirect through the Fain Living Trust. The form includes an explanatory footnote about the weighted-average price range. There are no disclosures here about any changes to board roles, pledging of shares, or plan-based transactions.
Eric S. Fain, amministratore di Orchestra BioMed Holdings, Inc. (OBIO), ha comunicato l'acquisto di 5.760 azioni ordinarie della societ脿 a un prezzo medio ponderato di 2,61 USD per azione. Dopo questa operazione, la persona che ha presentato la segnalazione detiene beneficiariamente 71.709 azioni indirettamente tramite il Fain Living Trust. La dichiarazione indica che l'acquisto 猫 il risultato di pi霉 operazioni aggregate in un prezzo medio ponderato e precisa che la segnalazione 猫 stata effettuata a titolo personale in qualit脿 di amministratore. In questo Modulo 4 non sono riportate transazioni in strumenti derivati, cessioni n茅 altri cambiamenti nella propriet脿.
Eric S. Fain, director de Orchestra BioMed Holdings, Inc. (OBIO), inform贸 la adquisici贸n de 5.760 acciones ordinarias de la compa帽铆a a un precio promedio ponderado de 2,61 USD por acci贸n. Tras esta operaci贸n, la persona informante posee de forma beneficiaria 71.709 acciones indirectamente a trav茅s del Fain Living Trust. El formulario se帽ala que la compra corresponde a varias transacciones agregadas a un precio promedio ponderado y aclara que la persona presenta la declaraci贸n a t铆tulo individual como director. En este Formulario 4 no se registran operaciones con derivados, enajenaciones ni otros cambios de propiedad.
鞓れ紑鞀ろ姼霛� 氚旍澊鞓る⿺霌� 頇�霐╈姢(Orchestra BioMed Holdings, Inc., OBIO)鞚� 鞚挫偓鞚� Eric S. Fain鞚� 氤错喌欤� 5,760欤茧ゼ 欤茧嫻 臧�欷戫弶攴犼皜瓴� 2.61雼煬鞐� 旆摑頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 鞚� 瓯半灅 頉� 鞁犼碃鞚胳潃 Fain Living Trust毳� 韱淀暣 臧勳爲鞝侅溂搿� 齑� 71,709欤茧ゼ 鞁れ 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊電� 頃措嫻 毵れ瀰鞚� 鞐煬 瓯半灅毳� 臧�欷戫弶攴犼皜瓴╈溂搿� 歆戧硠頃� 瓴冹瀯鞚� 氚濏瀳瓿� 鞛堨溂氅�, 鞁犼碃鞚胳潃 鞚挫偓搿滌劀 臧滌澑 氇呾潣搿� 鞁犼碃頃橁碃 鞛堨潓鞚� 氇呾嫓頃╇媹雼�. 鞚� Form 4鞐愳劀電� 韺岇儩靸來拡 瓯半灅, 觳橂秳 霕愲姅 旮绊儉 靻岇湢甓� 氤�瓴届潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
Eric S. Fain, administrateur d'Orchestra BioMed Holdings, Inc. (OBIO), a d茅clar茅 l'acquisition de 5 760 actions ordinaires de la soci茅t茅 au prix moyen pond茅r茅 de 2,61 USD par action. 脌 la suite de cette op茅ration, la personne d茅clarante poss猫de 脿 titre b茅n茅ficiaire 71 709 actions indirectement via le Fain Living Trust. Le d茅p么t pr茅cise que cet achat correspond 脿 plusieurs transactions agr茅g茅es en un prix moyen pond茅r茅 et indique que la personne d茅pose la d茅claration 脿 titre individuel en tant qu'administrateur. Aucune transaction d茅riv茅e, cession ou autre changement de propri茅t茅 n'est signal茅 dans ce Formulaire 4.
Eric S. Fain, Director von Orchestra BioMed Holdings, Inc. (OBIO), meldete den Erwerb von 5.760 Stammaktien des Unternehmens zu einem gewichteten Durchschnittspreis von 2,61 USD je Aktie. Nach dieser Transaktion besitzt die meldende Person wirtschaftlich 71.709 Aktien indirekt 眉ber den Fain Living Trust. Die Meldung weist darauf hin, dass der Kauf aus mehreren Transaktionen zu einem gewichteten Durchschnittspreis zusammengefasst wurde und dass die meldende Person individuell als Director meldet. In diesem Formular 4 sind keine Derivatgesch盲fte, Ver盲u脽erungen oder sonstigen 脛nderungen der Eigentumsverh盲ltnisse angegeben.
FAQ
What did OBIO director Eric S. Fain purchase according to the Form 4?
At what price were the OBIO shares purchased?
How many OBIO shares does the reporting person beneficially own after the transaction?
What is the reporting person's relationship to OBIO?
Were any derivative securities or dispositions reported in this Form 4?
